INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand. The single-dose vials are priced at a 50% or greater discount compared to the list price of all other incretin (GLP-1) medicines for obesity.

印第安纳波利斯，2024年8月27日/PRNewswire/--礼来公司（纽约证券交易所代码：LLY）今天宣布，Zepbound®（tirzepatide）2.5 mg和5 mg单剂量小瓶可用于标签上处方患者的自费，从而显着扩大了Zepbound的供应，以应对高需求。与所有其他用于肥胖的肠降血糖素（GLP-1）药物的标价相比，单剂量小瓶的价格折扣为50%或更高。

This new option helps millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage, and those who need to self-pay outside of insurance..

这一新选项帮助数百万肥胖成年人获得他们所需的药物，包括那些不符合Zepbound储蓄卡计划资格的人，那些没有雇主保险的人，以及那些需要在保险之外自费的人。。

'We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase supply of Zepbound in the U.S.,' said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. 'These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option.

礼来心脏代谢健康和礼来美国执行副总裁兼总裁帕特里克·琼森（PatrikJonsson）说：“我们很高兴与大家分享，Zepbound单剂量小瓶现在已经上市，进一步兑现了我们增加美国Zepbound供应的承诺。这些新小瓶不仅有助于我们满足对肥胖药物的高需求，还拓宽了寻求安全有效治疗选择的患者的渠道。

In a clinical study, the 5 mg maintenance dose helped patients achieve an average of 15% weight loss after 72 weeks of treatment and has been a powerful tool for millions of people with obesity looking to lose weight and keep it off.'.

在一项临床研究中，5毫克的维持剂量帮助患者在治疗72周后平均体重减轻了15%，并且已经成为数百万寻求减肥和减肥的肥胖症患者的有力工具。”

Lilly has created a new self-pay pharmacy component of LillyDirect where patients with a valid, on-label prescription from the health care provider of their choice can purchase the vials. Distributing the vials via this channel ensures patients and providers can trust they are receiving genuine Lilly medicine, building on the company's efforts to help protect the public from the dangers posed by the proliferation of counterfeit, fake, unsafe or untested knock-offs of Lilly's medications.

礼来公司（LillyDirect）创建了一个新的自费药房组件，患者可以从他们选择的医疗保健提供者那里获得有效的标签上的处方来购买这些药瓶。通过该渠道分发小瓶可确保患者和提供者相信他们正在接受真正的礼来药品，该公司努力帮助保护公众免受假冒、假冒、不安全或未经测试的礼来药品仿冒品扩散所带来的危险。

Lilly has also taken a vocal stance against the use of obesity medicine for cosmetic weight loss; a multi-step verification process will help ensure the vials are dispensed only to patients who have a valid, on-label electronic prescription from their health care provider. Patients can also purchase ancillary supplies, like syringes and needles, and will have access to important patient-friendly instructional materials on correctly administering the medicine via needle and syringe..

一个多步骤的验证过程将有助于确保这些药瓶只分发给拥有医疗保健提供者提供的有效标签上电子处方的患者。患者还可以购买辅助用品，如注射器和针头，并可以获得有关通过针头和注射器正确给药的重要患者友好教学材料。

'People living with obesity have long been denied access to the essential treatment and care needed to manage this serious chronic disease,' said James Zervos, chief operating officer, Obesity Action Coalition. 'Expanding coverage and affordability of treatments is vital to people living with obesity.

肥胖症行动联盟首席运营官詹姆斯·泽沃斯（JamesZervos）说，长期以来，肥胖症患者一直无法获得管理这种严重慢性病所需的基本治疗和护理扩大治疗的覆盖面和负担能力对肥胖患者至关重要。

We commend Lilly for their leadership in offering an innovative solution that brings us closer to making equitable care a reality. Now, it's time for policymakers, employers and insurers to work with pharmaceutical companies to ensure no one is left behind in receiving the care they deserve and need.' .

我们赞扬礼来在提供创新解决方案方面发挥的领导作用，使我们更接近实现公平护理。现在，是政策制定者、雇主和保险公司与制药公司合作的时候了，以确保没有人在接受他们应得和需要的护理方面落后。”。

A four-week supply of the 2.5 mg Zepbound single-dose vial is $399 ($99.75 per vial), and a four-week supply of the 5 mg dose is $549 ($137.25 per vial) – less than half the list price of other incretin medicines for obesity and in line with the Zepbound savings program for non-covered individuals. The self-pay channel enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance..

2.5毫克Zepbound单剂量小瓶的四周供应价格为399美元（每瓶99.75美元），5毫克剂量的四周供应价格为549美元（每瓶137.25美元），不到其他治疗肥胖的肠降血糖素药物标价的一半，并且符合Zepbound为未投保个人提供的储蓄计划。自助支付渠道通过删除第三方供应链实体并允许患者直接在保险之外获得储蓄，从而实现了透明的价格。。

'Despite obesity being recognized as a serious chronic illness with long-term consequences, it's often misclassified as a lifestyle choice, resulting in many employers and the federal government excluding medications like Zepbound from insurance coverage,' said Jonsson. 'Outdated policies and lack of coverage for obesity medications create an urgent need for more innovative solutions.

Jonsson说：“尽管肥胖被认为是一种严重的慢性疾病，具有长期后果，但它经常被错误地归类为一种生活方式选择，导致许多雇主和联邦政府将Zepbound等药物排除在保险范围之外。”过时的政策和肥胖药物缺乏覆盖范围，迫切需要更具创新性的解决方案。

Bringing Zepbound single-dose vials to patients will help more people living with obesity manage this chronic condition. We will also continue to advocate for a system that better aligns with the science.'.

将Zepbound单剂量小瓶带给患者将有助于更多肥胖患者控制这种慢性病。我们还将继续倡导一个更好地与科学保持一致的系统。”。

In a clinical study, tirzepatide 5 mg, along with a reduced calorie diet and increased physical activity, achieved an average of 15% weight loss over 72 weeks compared to 3.1% for placebo. Zepbound is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

在一项临床研究中，tirzepatide 5 mg，以及减少热量饮食和增加体力活动，在72周内平均体重减轻了15%，而安慰剂组为3.1%。Zepbound是第一个也是唯一一个激活GIP（葡萄糖依赖性促胰岛素多肽）和GLP-1（胰高血糖素样肽-1）激素受体的肥胖治疗方法。

Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or those who are overweight and also have weight-related medical problems, to lose weight and keep it off. Zepbound should be used with a reduced-calorie diet and increased physical activity.

Zepbound解决了超重的根本原因。它会降低食欲和你的进食量。Zepbound适用于肥胖的成年人，或超重且有与体重有关的医学问题的成年人，以减肥并保持体重。Zepbound应与减少卡路里饮食和增加体力活动一起使用。

It should not be used in children under 18 years of age or with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. Zepbound has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis, and it is unknown if patients with a history of pancreatitis are at higher risk for developing pancreatitis on Zepbound..

它不应该用于18岁以下的儿童，也不应该与其他含tirzepatide的产品或任何GLP-1受体激动剂药物一起使用。尚未对有胰腺炎病史或严重胃肠道疾病（包括严重胃轻瘫）的患者进行Zepbound研究，尚不清楚有胰腺炎病史的患者在Zepbound上发生胰腺炎的风险是否更高。。

Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 ml doses in a single-dose pen (autoinjector). The recommended maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.

Zepbound 也有每 0.5 毫升 2.5 毫克、5 毫克、7.5 毫克、10 毫克、12.5 毫克或 15 毫克剂量的单剂量笔（自动注射器）。推荐的维持剂量为每周一次皮下注射 5 毫克、10 毫克或 15 毫克。

About Lilly  Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

关于礼来 礼来是一家将科学转化为治疗的医药公司，旨在让世界各地的人们生活得更好。近150年来，我们一直在开创改变生活的发现，今天，我们的药物帮助了全球5100多万人。利用生物技术、化学和遗传医学的力量，我们的科学家正在迫切推进新发现，以解决世界上一些最重大的健康挑战：重新定义糖尿病护理；治疗肥胖并减少其最具破坏性的长期影响；推进与阿尔茨海默病的斗争；为一些最致命的免疫系统疾病提供解决方案；并将最难治疗的癌症转化为可控制的疾病。